Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators

Alexandre Bridoux; Huadong Cui; Evgeny Dyskin; Murat Yalcin; Shaker A Mousa

doi:10.1016/j.bmcl.2009.04.094

Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3259-63. doi: 10.1016/j.bmcl.2009.04.094. Epub 2009 Apr 24.

Authors

Alexandre Bridoux¹, Huadong Cui, Evgeny Dyskin, Murat Yalcin, Shaker A Mousa

Affiliation

¹ The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.

PMID: 19427201
DOI: 10.1016/j.bmcl.2009.04.094

Abstract

Novel Tetrac analogs were synthesized and then tested. Anti-angiogenesis efficacy was carried out using the Chick Chorioallantoic Membrane (CAM) model and the mouse matrigel model for angiogenesis. Pharmacological activities showed Tetrac can accommodate numerous modifications and maintain anti-angiogenesis activity.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / chemistry*
Angiogenesis Inhibitors / pharmacology
Animals
Chick Embryo
Chorioallantoic Membrane / blood supply
Chorioallantoic Membrane / drug effects
Drug Evaluation, Preclinical
Fibroblast Growth Factors / pharmacology
Hemoglobins / analysis
Mice
Structure-Activity Relationship
Thyroxine / analogs & derivatives*
Thyroxine / chemical synthesis
Thyroxine / chemistry
Thyroxine / pharmacology

Substances

Angiogenesis Inhibitors
Hemoglobins
Fibroblast Growth Factors
tetraiodothyroacetic acid
Thyroxine